***********************************
Brakke Consulting’s
Animal Health News & Notes for October 20, 2023
Copyright © Brakke Consulting
Editor: Lynn Fondon DVM MBA
************************************
IN THE NEWS:
Brakke Consulting News
2023 Flea Control & Heartworm Markets report
Other News
ADM
Aimia Pet Health
Assisi Pet Care Group Limited
Belvoir Media Group
Better Choice
Bond Vet
Boost Capital Partners
Creature Comforts
Dalan Animal Health
Evonik
Hanaco VC
Hill’s
Merck
MWI
Nutramax
Pangolia
Protix
Red Collar Pet Foods
Shandog Vland Biotech
Shepherd Veterinary Software
Sunshine Mills
Talisman Capital Partners
Torch Capital
Tyson Foods
Umbrella AI Studio
Veterinary Practice Partners
Virbac
Warburg Pincus
Wind Point Partners
Zoetis
*********************************************
Brakke Consulting
2023 US FLEA CONTROL AND HEARTWORM MARKETS REPORT
EARLY-BIRD DISCOUNT ENDS NOV. 17
Are you on top of the trends in the largest market segment in companion animal health? Brakke Consulting will soon be publishing our 2023 report on the US Flea Control and Heartworm Markets.
The report includes valuable information on the US market for small animal parasiticides including:
– Product descriptions, prices (veterinarian cost and online pricing), and sales for the leading veterinary flea, tick and heartworm products
– an overview of the veterinary and OTC flea control markets
– discussion of new product launches, including NEXGARD PLUS and NEXGARD COMBO
– 2023 survey of 300+ veterinarians
– 2023 survey of 500 pet owners
The report on the US Flea Control & Heartworm Markets will be available for a purchase price of $7,495 if ordered by FRIDAY, NOVEMBER 17, and $7,995 after that date.
Please contact Dr. Lynn Fondon at 336-396-3916 or lfondon@brakkeconsulting.com to pre-order the report, or for more information visit our website.
**************************************
COMPANY NEWS RELEASES
- Zoetis announced that Librela (bedinvetmab), a once-monthly injectable monoclonal antibody for dogs with osteoarthritis, is now available for ordering. (company announcement)
- Merck Animal Health announced that its caninized monoclonal antibody gilvetmab has received conditional license approval for the treatment of dogs with mast cell tumors and for treatment of dogs with melanoma by the USDA Center for Veterinary Biologics (CVB), and is now available to board certified veterinary oncologists across the US. (company press release)
- Virbac announced the launch of Zenidog, a line of long-acting pheromone products for dogs. (company announcement)
- Hill’s Pet Nutrition announced it has opened a 365,000-sq.-ft “smart” manufacturing facility that will increase the company’s production capacity for canned pet food and provide a runway for continued expansion of Hill’s Science Diet and Prescription Diet brands. (com)
- MWI Animal Health announced that Shepherd Veterinary Software is now fully and seamlessly integrated with MWI’s AllyDVM client engagement platform. (Businesswire)
- Nutramax and ADM’s probiotic supplements brand, ADM Protexin, announced the expansion of their longstanding partnership that will allow ADM Protexin to manage certain Nutramax brands in Europe and a number of APAC markets, with the aim to expand further internationally. (Pet Age)
- Better Choice Company announced it has signed a research and development partnership with Aimia Pet Health to develop a GLP1 supplement for overweight pets under its Halo brand. (Yahoo Finance)
- Sunshine Mills announced it has acquired Red Collar Pet Foods’ production facility in Joplin, Missouri, providing Sunshine Mills with extra capacity to produce baked and cold-formed pet treats. The facility holds over 200,000 square feet of production and warehouse space. Financial terms were not disclosed. (Just-food.com)
- Veterinary Practice Partners announced that El Paseo Animal Hospital in Palm Desert, California, has joined the group as its 140th partner across 27 states. (Todays Veterinary Business)
- Bond Vet, an urgent and primary veterinary care provider, announced it has secured a $50 million investment led by existing investors Warburg Pincus and Talisman Capital Partners. (Axios)
- Umbrella AI Studio announced the launch of its app, Umbrella Vet. The app provides immediate AI recommendations for a wide range of pet care topics, and offers the opportunity for users to engage in real-time video consultations with licensed veterinarians. com)
- Tyson Foods and Protix announced an agreement for a two-fold investment to support the growth of the emerging insect ingredient industry and expand the use of insect ingredient solutions. Through a direct equity investment, Tyson Foods will acquire a minority stake in Protix to help fund its global expansion. Additionally, Tyson Foods and Protix have entered a joint venture for the operation and construction of an insect ingredient facility in the continental US. (Feedstuffs)
- Pangolia, a digital media and e-commerce startup, announced an all-cash acquisition of the Catster and Dogster brands from Belvoir Media Group. Financial terms were not disclosed. (Pet Business)
- CANADA The Canadian Center for Veterinary Biologics (CCVB) announced the conditional licensing of Dalan Animal Health‘s novel vaccine for American Foulbrood (AFB) in honeybees. (DVM360)
- UK Wind Point Partners announced it has acquired Assisi Pet Care Group Limited, a UK-based producer of premium and natural dog and cat foods and treats. Financial terms were not disclosed. (Pet Business)
- CHINA Evonik and Shandog Vland Biotech announced a joint venture in China with a focus on optimizing the gut health of farmed animals. Evonik Vland Biotech (Shandong) Co. Ltd. will be headquartered in China and will build on the companies’ existing probiotic-focused partnership. (Feednavigator)
- UK Pet tech startup Creature Comforts announced it has raised GBP 7 million ($8.5 million) in seed capital to provide veterinary care through an integrated approach, combining telehealth consultations with digitally enabled in-person clinics. The cash injection will be used to design, open and staff its first two clinics; and to fund the build of a proprietary app by an in-house tech team, supporting 24/7 virtual care and customer queries, and letting vets work flexibly and from home. The round was co-led by Torch Capital, Hanaco VC, and Boost Capital Partners. (eu)
*********************************************
ANIMAL HEALTH STOCK PRICE TRACKER
***********************************
ANIMAL HEALTH NEWS
- US – DOG NUTRITION RESEARCH BSM Partners, along with a group of veterinary cardiologists, found in a seven-month study that grain-free diets had no negative effect on canine cardiac function and didn’t lead to the development of dilated cardiomyopathy. Researchers formulated four canine diets, two grain-free and two grain-inclusive. The research appeared in a peer-reviewed article in Frontiers in Animal Science. (PRNewswire)
************************************
BRAKKE CONSULTING VIEWPOINT
Two items in the newsletter today strengthened my excitement for monoclonal antibodies in veterinary medicine. With Zoetis now shipping Librela, the monoclonal antibody for pain in dogs, and Merck receiving conditional approval by the USDA’s CVB for their oncology product for dogs, gilvetmab, it seems like our industry should be excited. Why?
First, it shows that animal health companies can and will bring new and innovative drug technologies to the veterinary market. The market wants them and is willing to pay for them (think Cytopoint and Solensia, both from Zoetis). Secondly, innovation is also great for the sales and marketing teams of animal health companies – it gives them new products to detail and should help deliver better medicines to veterinarians and outcomes for pet owners. Third, because monoclonal antibodies are injected, rather than given orally, this will drive pets into clinics more frequently and will help keep the veterinarian and the veterinary technicians in the middle of the relationship between the pet and the pet owner.
We know from the results of our Sales Force Effectiveness Study that veterinarians really do differentiate animal health companies based on their ability to bring innovative products and services to them. Our data shows that innovation is a driver of overall company performance and overall trust in the company. We are clearly excited about the many positive opportunities and outcomes that monoclonal antibodies will bring to veterinary medicine.
Bob Jones
***********************************
YOUR VIEW
Last week, we asked you what you thought consumers response might be to gene-edited pork. Over half of our respondents (55%) said that consumers would buy it just like non-gene-edited pork but 30% said that they won’t buy it. About 13% said that consumers won’t buy it and it will reduce their consumption of normal pork, while 3% said they will stop buying pork. Looks like the industry needs to tread carefully.
This Week
This week, let’s see what you think of the new Librella product that Zoetis is now shipping.
English (United States) 
Portuguese